Pharmacokinetics of Hydrochlorothiazide, Losartan and E3174 after Oral Doses of Losartan and Losartan/Hydrochlorothiazide in Healthy Chinese Male Volunteers
Sha Liu, Fan-Long Bu, Chun-Min Wei, Gui-Yan Yuan, Ben-Jie Wang, Rui-Chen Guo
DOI: 10.4236/pp.2012.31002   PDF    HTML     8,032 Downloads   16,768 Views   Citations


Aims: A simple and highly sensitive LC-MS method was used to determine the concentrations of losartan, its major active metabolite E3174 and hydrochlorothiazide in human plasma and pharmacokinetic characteristics and metabolism phenotype observation after administration of losartan tablets and losartan/hydrochlorothiazide combination tablets. Methods: An open, randomized cross-over single-dose study was designed in forty healthy male volunteers, A single-dose of 50 mg losartan tablets or 50 mg losartan/12.5 mg hydrochlorothiazide combination tablets was orally given and blood samples were collected at scheduled time. A LC-MS method was established and evaluated for determining the plasma concentrations of losartan, E3174 and hydrochlorothiazide. The pharmacokinetic parameters and characteristic of metabolism phenotypes were calculated and compared via this test. Results: The elimination rate of E3174 (t1/2) was significantly shorter (P < 0.05) and the AUC0–t was lower (P < 0.05) for administration of combination tablets. The rest of pharmacokinetic parameters of losartan and E3174 have no significant differences. Among all subjects, three phenotypes were observed: the poor, the intermediate and the extensive metabolism. Conclusion: It is indicated that the test and reference tablets were bioequivalent, and that hydrochlorothiazide could significantly alter the t1/2, AUC0–t and AUC0–inf of E3174.

Share and Cite:

S. Liu, F. Bu, C. Wei, G. Yuan, B. Wang and R. Guo, "Pharmacokinetics of Hydrochlorothiazide, Losartan and E3174 after Oral Doses of Losartan and Losartan/Hydrochlorothiazide in Healthy Chinese Male Volunteers," Pharmacology & Pharmacy, Vol. 3 No. 1, 2012, pp. 7-14. doi: 10.4236/pp.2012.31002.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Z. X. Zhao, Q. X. Wang, E. W. Tsai and X. Z. Qin. “Identification of Losartan Degradates in Stressed Tablets by LC-MS and LC-MS/MS,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 20, No. 1-2, 1999, pp. 129-136. doi:10.1016/S0731-7085(99)00004-7
[2] D. J. Triggle. “Angiotensin II Receptor Antagonism: Losartan-Sites and Mechanisms of Action,” Clinical Therapeutics, Vol. 17, No. 6, 1995, pp. 1004-1030. doi:10.1016/0149-2918(95)80080-8
[3] T. Tanner, S. Aspley, A. Munn and T. Thomas. “The Pharmacokinetic Profile of a Novel Fixed-Dose Combination Tablet of Ibuprofen and Paracetamol,” BMC Clinical Pharmacology, Vol. 10, No. 10, 2010, pp. 989- 992.
[4] L. H. Liu, P. Z. Liao and J. G. Duan. “Effect of Hyperglycemia on Protein Kinase C in Retina of diabetic rats,” Journal of Changzhi Medical College, Vol. 3, No. 17, 2003, pp. 3-5.
[5] T. Matsumoto, K. Ishida, K. Kamata, et al., “Mechanisms Underlying the Losartan Treatment-Induced Improvement in the Endothelial Dysfunction Seen in Mesenteric Arteries from Type 2 Diabetic Rats,” Pharmacological Research, Vol. 3, 2010, pp. 1-11.
[6] M. Polinko, K. Riffel, H.C. Song and M.W. Lo, “Simultaneous Determination of Losartan and EXP3174 in Human Plasma and Urine Utilizing Liquid Chromatography/ Tandem Mass Spectrometry,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 33, No. 1, 2003, pp. 73-84. doi:10.1016/S0731-7085(03)00348-0
[7] R. N. Chena, H. O. Hob, C. Y. Yu and M. T. Sheub, “Development of Swelling/Floating Gastroretentive Drug Delivery System Based on a Combination of Hydroxyethyl Cellulose and Sodium Carboxymethyl Cellulose for Losartan and Its Clinical Relevance in Healthy Volunteers with CYP2C9 Polymorphism,” European Journal of Pharmaceutical Sciences, Vol. 39, No. 1, 2010, pp. 82-89. doi:10.1016/j.ejps.2009.10.015
[8] P. Yang, L. Li, J. Sun and Z. G He, “Bioequivalent Evaluation of two Losartan/Hydrochlorothiazide Compound Tablets in Healthy Chinese Male Volunteers,” Journal of Chinese Pharmaceutical Sciences, Vol. 15, No. 3, 2006, pp. 162-167.
[9] B. Prasaja, L. Sasongko, Y. Harahap, et al., “Simultaneous Quantification of Losartan and Active Metabolite in Human Plasma by Liquid Chromatography-Tandem Mass Spectrometry Using Irbesartan as Internal Standard,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 49, 2009, pp. 862-867. doi:10.1016/j.jpba.2009.01.007
[10] P. Yang, Y. J. Wang, L. Li, J. Sun and Z. G. He, “Bioequivalence of Losartan Capsule and Tablet in Healthy Volunteers,” The Chinese Journal of Clinical Pharmacology, Vol. 104, 2006, pp. 436-439.
[11] M. Lusina, T. Cindri, J. Tomai, et al., “Stability Study of Losartan/Hydrochlorothiazide Tablets,” International Journal of Pharmaceutics, Vol. 291, 2005, pp. 127-137. doi:10.1016/j.ijpharm.2004.07.050
[12] P. Liu, L. Sun, B. J. Wang and R. C. Guo, “Development and Validation of a Sensitive Method for the Determination of Tramadol Plasma and Urine,” European Journal of Drug Metabolism and Pharmacokinetics, Vol. 34, 2009, pp. 185-192. doi:10.1007/BF03191172
[13] N. R. Pilli, J. K. Inamadugu and S. Rao, “Simultaneous Determination of Atorvastatin, Amlodipine, Ramipril and Benazepril in Human Plasma by LC-MS/MS and Its Application to a Human Pharmacokinetic Study,” Biomedical Chroma-tography, Vol. 25, No. 4, 2011, pp. 439-449. doi:10.1002/bmc.1462

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.